Fintel reports that on May 3, 2023, Atlantic Equities reiterated coverage of Idexx Laboratories (NASDAQ:IDXX) with a Overweight recommendation.
Analyst Price Forecast Suggests 22.24% Upside
As of April 24, 2023, the average one-year price target for Idexx Laboratories is 571.33. The forecasts range from a low of 505.00 to a high of $630.00. The average price target represents an increase of 22.24% from its latest reported closing price of 467.38.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Idexx Laboratories is 3,663MM, an increase of 6.76%. The projected annual non-GAAP EPS is 9.59.
What is the Fund Sentiment?
There are 1889 funds or institutions reporting positions in Idexx Laboratories. This is an increase of 83 owner(s) or 4.60% in the last quarter. Average portfolio weight of all funds dedicated to IDXX is 0.42%, an increase of 21.96%. Total shares owned by institutions increased in the last three months by 0.70% to 86,373K shares. 
The put/call ratio of IDXX is 1.01, indicating a bearish outlook.
What are Other Shareholders Doing?
Fundsmith LLP holds 3,444K shares representing 4.15% ownership of the company. In it's prior filing, the firm reported owning 3,621K shares, representing a decrease of 5.14%. The firm increased its portfolio allocation in IDXX by 14.59% over the last quarter.
Alliancebernstein holds 3,241K shares representing 3.91% ownership of the company. In it's prior filing, the firm reported owning 2,907K shares, representing an increase of 10.31%. The firm increased its portfolio allocation in IDXX by 29.77% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,517K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 2,480K shares, representing an increase of 1.46%. The firm increased its portfolio allocation in IDXX by 17.35% over the last quarter.
Bamco holds 2,374K shares representing 2.86% ownership of the company. In it's prior filing, the firm reported owning 2,387K shares, representing a decrease of 0.58%. The firm increased its portfolio allocation in IDXX by 29.39% over the last quarter.
Geode Capital Management holds 1,920K shares representing 2.31% ownership of the company. In it's prior filing, the firm reported owning 1,891K shares, representing an increase of 1.50%. The firm increased its portfolio allocation in IDXX by 17.54% over the last quarter.
Idexx Laboratories Background Information
(This description is provided by the company.)
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, offering diagnostic and software products and services that deliver solutions and insights to practicing veterinarians around the world. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk and point-of-care and laboratory diagnostics for human medicine. Headquartered in Maine, IDEXX employs more than 9,000 people and offers products to customers in over 175 countries.
See all Idexx Laboratories regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
